Table 2.
Week 12 endoscopic remission among participants with Modified Multiplier of the Simple Endoscopic Score for Crohn’s Disease ≥ 22.5 at baseline (n = 100).
| Endoscopic remission | Overall (n = 100) | Adalimumab (n = 51) | Placebo (n = 49) | p value (Adalimumab vs placebo) | Number needed to treat (95% CI) |
|---|---|---|---|---|---|
| Absence of mucosal ulcerations | 19 (19.0) | 12 (23.5) | 7 (14.3) | 0.239 | 10.9 (10.8-11.1) |
| SES-CD of 0 | 6 (6.0) | 5 (9.8) | 1 (2.0) | 0.102 | 12.8 (12.7-12.9) |
| SES-CD < 3 | 9 (9.0) | 8 (15.7) | 1 (2.0) | 0.017 | 7.3 (7.2-7.4) |
| SES-CD < 4 | 17 (17.0) | 15 (29.4) | 2 (4.1) | 0.001 | 4 (3.9-4.1) |
| MM-SES-CD < 22.5 | 53 (53.0) | 33 (64.7) | 20 (40.8) | 0.017 | 4.2 (4.0-4.4) |
| MM-SES-CD ≥ 20% reduction from baseline | 62 (62.0) | 38 (74.5) | 24 (49.0) | 0.009 | 3.9 (3.7-4.1) |
| MM-SES-CD ≥ 40% reduction from baseline | 51 (51.0) | 33 (64.7) | 18 (36.7) | 0.005 | 3.6 (3.4-3.8) |
| SES-CD ≥ 20% reduction from baseline | 51 (51.0) | 32 (62.8) | 19 (38.8) | 0.017 | 4.2 (4.1-4.3) |
| SES-CD ≥ 50% reduction from baseline | 39 (39.0) | 27 (52.9) | 12 (24.5) | 0.004 | 3.5 (3.3-3.7) |